Get the Stockscreener App
0.199
16.37%
0.028
After Hours:
.23
0.031
+15.58%
Hepion Pharmaceuticals Inc Stock (HEPA) Latest News
Hepion Pharmaceuticals (NASDAQ:HEPA) Shares Up 1.3% – Here’s Why - Defense World
The HEPA Stock Puzzle: Unraveling Hepion Pharmaceuticals Inc’s Fluctuating Performance - The InvestChronicle
A look at HEPA’s current quarter earnings estimates - US Post News
Evaluating the Impact of 3.43 Increase on Hepion Pharmaceuticals Inc’s (HEPA) Stock - The News Heater
Gaining Ground: Hepion Pharmaceuticals Inc (HEPA) Closes Higher at 0.17, Up 3.43 - The Dwinnex
Form DEF 14A Hepion Pharmaceuticals, For: Feb 07 - StreetInsider.com
An analyst sees good growth prospects for Hepion Pharmaceuticals Inc (HEPA) - SETE News
Hepion Pharmaceuticals Inc (HEPA) Stock: A Year of Decreases and Increases - The InvestChronicle
Understanding HEPA’s financial ratios: A beginner’s guide - US Post News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Hepion Pharmaceuticals to Participate in BIO CEO & Investor Digital Conference - ACCESS Newswire
Hepion Announces Closing of Public Offering of Common Stock - ACCESS Newswire
Hepion Pharmaceuticals launches public offering for proceeds of up to $9M; shares tumble - MSN
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales - Benzinga
Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earnings - Benzinga
Stock market today: Star Fashion Culture Holdings jumped by 680.92% while Hepion Pharmaceuticals saw increase of 147.54% in early trading - Business Upturn
Hepion Pharmaceuticals launches $9 million stock offering - Investing.com India
Hepion Pharmaceuticals announces $9M public offering - TipRanks
Hepion Pharmaceuticals Announces $9.0 Million Public Offering - The Manila Times
Hepion Pharmaceuticals Announces $9M Public Offering with Dual Warrant Structure - StockTitan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
HEPA stock touches 52-week low at $0.43 amid market challenges - Investing.com India
Hepion Pharmaceuticals faces potential Nasdaq delisting - Investing.com
Hepion Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com UK
HEPA stock touches 52-week low at $0.43 amid market challenges By Investing.com - Investing.com South Africa
Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Quotes, Forecast and News Summary - Benzinga
HEPA stock touches 52-week low at $0.46 amid market challenges - Investing.com Canada
Comparing Novo Nordisk A/S (NYSE:NVO) and Hepion Pharmaceuticals (NASDAQ:HEPA) - Defense World
HEPA stock touches 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa
HEPAHepion Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Hepion Pharmaceuticals Terminates Merger with Pharma Two B - TipRanks
HEPA stock touches 52-week low at $0.49 amid market challenges - Investing.com
Hepion Pharmaceuticals cancels merger and stockholder meeting By Investing.com - Investing.com Canada
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. - The Manila Times
Hepion Pharmaceuticals Terminates Strategic Merger with Pharma Two BMajor Deal Cancelled - StockTitan
Oligonucleotide Therapy Market Key Players AnalysisBPCI - openPR
Pharma Two B Announces Poster Presentation on P2B001 at the - GlobeNewswire
Hepion Pharmaceuticals (NASDAQ:HEPA) Shares Down 4.1% – Here’s What Happened - Defense World
Hepion urges shareholder support for Pharma Two B merger - Investing.com India
Hepion urges shareholder support for Pharma Two B merger By Investing.com - Investing.com Canada
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - The Manila Times
Hepion Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com Nigeria
Hepion Pharmaceuticals faces Nasdaq delisting risk - Investing.com India
HEPA (Hepion Pharmaceuticals) 3-Year EPS without NRI Growth Rate : 35.30% (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Accounts Receivable : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Long-Term Debt & Capital Leas - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Analysis of ARMISTICE CAPITAL, LLC's Recent Transaction in Hepio - GuruFocus.com
Hepion Pharmaceuticals Inc (CTVRP) Quarterly 10-Q Report - Quartzy
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger - The Manila Times
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce - GlobeNewswire
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):